Anticoagulation for the Management of VTE in the NOAC era

Sunday 7 July, 13:15 – 14:30
Melbourne Room 1, Convention Centre Level 2

The Evolving Landscape of Anticoagulation in VTE
Alexander Gallus, Australia (Chair)

Improving VTE Treatment in Clinical Practice: NOACs vs LMWH/VKA
Jennifer Curnow, Australia

Clinical Dilemmas in VTE Management
Cihan Ay, Austria

Developments in Anticoagulation for Cancer-Associated Thrombosis
Ander Cohen, UK

Q&A
All

LMWH; low-molecular-weight heparin, NOAC; non-vitamin K antagonist oral anticoagulant
VKA; vitamin K antagonist, VTE; venous thromboembolism

This Satellite Symposium is fully organised and supported by:

Bristol-Myers Squibb  Pfizer

Date of preparation: May 2019  |  PP-ELI-EUR-1894

Bristol-Myers Squibb, 4 Nexus Ct, Mulgrave VIC 3170, Australia | Pfizer, Level 15/18, 151 Clarence St, Sydney NSW 2000, Australia